MG1 MA3

Drug Profile

MG1 MA3

Alternative Names: Ad MAGEA3; Marabex; MG1 Maraba/MAGE-A3; MG1-MAGEA3; MG1MA3

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Children's Hospital of Eastern Ontario; McMaster University; University of Ottawa
  • Developer National Cancer Institute (Canada); Turnstone Biologics
  • Class Cancer vaccines; Oncolytic viruses
  • Mechanism of Action Immunostimulants; Neoplasm antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Dec 2016 Phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater) in Canada (IV) (NCT02879760)
  • 22 Aug 2016 Turnstone Biologics plans a phase I/II trial for Non-small cell lung cancer in Canada (NCT02879760)
  • 10 Dec 2013 Pharmacodynamic data from a preclinical study in Melanoma released by Turnstone
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top